SightfileU.S. market data from official filings

MBX BIOSCIENCES INC (MBX)

Name: MBX BIOSCIENCES INC (MBX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001776111 · EDGAR filings · Updated 2026-07-13

MBX BIOSCIENCES INC (MBX) has reported institutional ownership of 110.6%, with 157 institutional managers holding positions valued at $1.57B per the latest 13F reporting period.

Institutional ownership

110.6%

Institutional managers

157

Reported 13F value

$1.57B

Insider activity

10 trans.

$13.1M net buying

Latest updates

2026-07-13 — Current report (8-K) filed
2026-07-08 — SCHEDULE 13G/A filed
2026-07-08 — SCHEDULE 13G/A filed
2026-06-24 — SCHEDULE 13G filed
2026-06-12 — Current report (8-K) filed
2026-06-10 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, MBX BIOSCIENCES INC has 157 institutional holders and institutional ownership of 110.6%.

Insider activity

Insiders reported 10 transactions (5 buys, 0 sells) across 6 reporting insiders, with a net reported value of $13.1M.

Related companies

HEARTFLOW INC (HTFL) · AMYLYX PHARMACEUTICALS INC (AMLX) · IMMUNOCORE HLDGS PLC (IMCR) · HARMONY BIOSCIENCES HLDGS IN (HRMY) · ANAPTYSBIO INC (ANAB) · MAZE THERAPEUTICS INC (MAZE)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.